Exploratory analysis of liquid biopsy for the predictive factors associated with outcome of PD-1 Pathway Blockade in Multicenter Study
Not Applicable
- Conditions
- non-small cell lung cancer
- Registration Number
- JPRN-jRCT1032220559
- Lead Sponsor
- Ohe Yuichiro
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Patients who meet the eligibility criteria of the most recent JCOG 1701 (to confirm the non-inferiority of survival of discontinuation of PD-1 pathway inhibitors versus their continuation in patients with advanced or recurrent non-small-cell lung cancer who have had no reccurence to PD-1 pathway inhibitors for 12 months or longer) protocol and who are not participating in JCOG 1701
Patients who have given their written consent to participate in this study
Patients who are able to provide tumor tissue samples necessary for the study
Exclusion Criteria
Patients who do not meet the eligibility criteria in the most recent JCOG1701 protocol or are currently participating in JCOG1701
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluate MRD (minimum residual disease) by ctDNA (circulating tumor DNA) to find the biomarker for logterm effective of PD-1 pathway inhibitor.
- Secondary Outcome Measures
Name Time Method